NeoVas Bioresorbable Coronary Scaffold Registry Study

NCT ID: NCT02305472

Last Updated: 2017-03-09

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 825 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-11-30
• Study Completion Date: 2020-09-30

Brief Summary

The NeoVas Bioresorbable Coronary Scaffold Registry Trial is a prospective, multi-center, single arm registry trial based on the NeoVas FIM study which verified the safety and effectiveness of NeoVas initially. This study is to evaluate the safety and effectiveness of NeoVas sirolimus-eluting bioresorbable coronary scaffold in the treatment of patients with de novo coronary lesion.

Detailed Description

Approximately 825 subjects will be enrolled and receive NeoVas BCS(Lepu Medical Technology (Beijing) Co.,Ltd). Subjects will have clinical follow-up at 30, 90, 180 and 270 days and at 1,2,3,4 and 5 years. The primary endpoint is target lesion failure(TLF) at 1 year follow-up.

Conditions

Coronary Artery Disease

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

NeoVas BCS

The NeoVas sirolimus-eluting bioresorbable coronary scaffold system is a PLLA-based polymer scaffold and contains the antiproliferative drug sirolimus.

Group Type: EXPERIMENTAL

NeoVas BCS

Intervention Type: DEVICE

Subjects receiving NeoVas BCS

Interventions

NeoVas BCS

Subjects receiving NeoVas BCS

Intervention Type: DEVICE

Other Intervention Names

NeoVas Bioresorbable Coronary Scaffold

Eligibility Criteria

Inclusion Criteria

• Age must be 18-75 years, men or unpregnant women.
• Patient must have evidence of myocardial ischemia, suitable for elective PCI. Subjects with stable angina or silent ischemia and <70% diameter stenosis must have objective sign of ischemia as determined by one of the following, echocardiogram, nuclear scan, ambulatory ECG or stress ECG. In the absence of noninvasive ischemia, fractional flow reserve(FFR) must be done and indicative of ischemia.
• Patients with one or two de novo lesions located in different epicardial vessels.
• Target lesion must be≤20mm in length(visual estimation)and 2.75 to 3.75 mm in diameter(Online QCA).
• Target lesion is with a visually estimated stenosis of ≥70%(or≥50% and evidence of myocardial ischemia) with a TIMI flow of ≥1.
• The target lesion can be covered by one scaffold(except the rescue scaffold).
• Patient must be an acceptable candidate for coronary artery bypass graft.
• Patient or a legally authorized representative must provide written Informed Consent prior to any study related procedure.

Exclusion Criteria

• Patients has had a known diagnosis of acute myocardial infarction(AMI) within 7 days preceding the procedure; CK and CK-MB have not returned within normal limits at the time of procedure.
• Chronic total occlusion lesions (TIMI 0 grade blood flow prior to implantation), left trunk vessel lesion, ostial lesion, multi-branch lesions needing treated, bifurcation lesion (diameter ≥2.0mm, branch opening stenosis exceeds 50% or need balloon expansion) and bridge vessel lesions; there is thrombus visible in the target blood vessels.
• Severe calcified lesions and twisted lesions which cannot be pre-expanded, and lesions unsuitable for delivering and expanding stents.
• In-stent restenosis lesion.
• Patient has undergone previous stenting anywhere within the target vessel(s) within the previous 12 months, or will require stenting within the target vessel(s) within 1 year after the study procedure; target vessels that has been implanted with stents.
• Severe heart failure(over NYHA III grade ), or left ventricular ejection fraction(LVEF)<40%( supersonic inspection or left ventricular radiography ).
• Known renal insufficiency(eGFR<60 ml/min, serum creatinine>2.5mg/dL, or subject on dialysis).
• Patients with hemorrhage tendency, an active digestive ulcer history, a cerebral hemorrhage or subarachnoid hemorrhage history, or cerebral apoplexy within half a year, and these patients who contraindicate against platelet inhibitors and anticoagulant therefore cannot bear anticoagulation treatment.
• Patient has a known hypersensitivity or contraindication to aspirin, clopidogrel, ticagrelor or prasugrel, heparin, contrast agent, polylactic acid or sirolimus that cannot be adequately pre-medicated.
• Life expectancy < 12 months.
• Patient is participating in another device or drug study that has not reached the primary endpoint of the study.
• Patient's inability to fully cooperate with the study protocol.
• Patient has a heart transplant.
• Patient has current unstable arrhythmias, such as high risk ventricular premature beat and ventricular tachycardia.
• Patient is receiving or scheduled to receive chemotherapy for malignancy within 30 days prior to or after the procedure.
• Patient is receiving immunosuppression therapy and has known immunosuppressive or autoimmune disease.
• Patient is receiving or scheduled to receive chronic anticoagulation therapy (e.g., heparin, warfarin).
• Elective surgery is planned within the first 6 months after the procedure that will require discontinuing either aspirin, clopidogrel, ticagrelor or prasugrel.
• Platelet count<100,000 cells/mm3 or>700,000 cells/mm3, a WBC of<3,000 cells/mm3, or documented or suspected liver disease.
• Patient has extensive peripheral vascular disease that precludes safe 6 French sheath insertion.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Lepu Medical Technology (Beijing) Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Yaling Han, MD

Role: STUDY_CHAIR

The general hospital of Shenyang military region

Guosheng Fu

Role: PRINCIPAL_INVESTIGATOR

Sir Run Run Shaw Hospital

Bo Xu

Role: PRINCIPAL_INVESTIGATOR

Beijing Fuwai hospital, National center for cardiovascular diseases China

Yao-Jun Zhang

Role: PRINCIPAL_INVESTIGATOR

Nanjing First Hospital, Nanjing Medical University

Locations

Anhui Provincial Hospital

Hefei, Anhui, China

Beijing Anzhen Hospital, Capital Medical University

Beijing, Beijing Municipality, China

General Hospital of Armed Police Forces

Beijing, Beijing Municipality, China

Aerospace Center Hospital

Beijing, Beijing Municipality, China

Fujian Medical University Union Hospital

Fuzhou, Fujian, China

The First Hospital of Lanzhou University

Lanzhou, Gansu, China

Nanfang Hospital Southern Medical University

Guangzhou, Guangdong, China

The First Affiliated Hospital of Guangxi Medical University

Nanning, Guangxi, China

Bethune Peace Hospital of PLA

Shijiazhuang, Hebei, China

Renmin Hospital of Wuhan University

Wuhan, Hubei, China

Wuhan General Hospital of Guangzhou Military

Wuhan, Hubei, China

Xiangya Hospital Central South University

Changsha, Hunan, China

Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School

Nanjing, Jiangsu, China

Zhongda Hospital Southeast University

Nanjing, Jiangsu, China

Jiangsu Province Hospital

Nanjing, Jiangsu, China

The general hospital of Shenyang military region

Shenyang, Liaoning, China

Renji Hospital Shanghai Jiaotong University School of Medicine

Shanghai, Shanghai Municipality, China

Shanghai Tenth People'S Hospital of Tongji University

Shanghai, Shanghai Municipality, China

Changhai Hospital of Shanghai

Shanghai, Shanghai Municipality, China

Xijing Hospital, the Fourth Military Medical University

Xi’an, Shanxi, China

The First Affiliated Hospital of Xi'An Jiaotong University

Xi’an, Shanxi, China

Chengdu Military General Hospital

Chengdu, Sichuan, China

Affiliated Hospital of The Chinese People's Armed Police Forces Logistic College

Tianjin, Tianjin Municipality, China

Tianjin first center hospital

Tianjin, Tianjin Municipality, China

Kunming General Hospital of Chengdu Military Region

Kunming, Yunnan, China

The First Affiliated Hospital, Zhejiang University

Hangzhou, Zhejiang, China

Sir Run Run Shaw Hospital,School of Medicine, Zhejiang University

Hangzhou, Zhejiang, China

Countries

China

Other Identifiers

LPM-201403

Identifier Type: -

Identifier Source: org_study_id